Identification of PI3Kα inhibitors through pharmacophore design and drug repositioning†
DOI:
https://doi.org/10.24265/horizmed.2024.v24n3.06Keywords:
PI-3K, Molecular Docking Simulation , Computational Biology , Neoplasms , PharmacophoreAbstract
Objective: PI3K is one of the most frequently mutated proteins in cancer, resulting in changes to its functions in regulating metabolism, immunity, among others. Despite the identification of specific drugs targeting PI3K, significant resistance to
these therapies has been observed. Therefore, the search for new inhibitors is crucial. This project proposes a strategy based on in silico computational tools for screening Food and Drug Administration (FDA)-approved drugs, aiming to evaluate their potential for drug repositioning. Materials and methods: This study obtained the sequence of PI3Kα from UniProt Knowledgebase and its three-dimensional structure from AlphaFold Protein Structure Database, which were then coupled with adenosine triphosphate (ATP) and its selective inhibitors: inavolisib, taselisib, CH5132799, alpelisib and ZSTK474. Drug-protein interaction analysis
was performed using Protein-Ligand Interaction Profiler (PLIP) and its visualization was done in PyMOL. Based on this information, pharmacophores were generated as models for virtual screening using PHARMIT and the FDA-approved drug
library (https://pharmit.csb.pitt.edu/search.html).
Results: Key atomistic positions of drug-protein interactions were identified based on the selective PI3Kα inhibitors interaction, leading to the generation of nine pharmacophores. A virtual screening resulted in 22 drugs that met the
proposed criteria, out of which 10 had binding energy values (kcal/mol) equal to or higher than the PI3Kα inhibitors. Subsequently, three drugs with potential use for drug repositioning were selected. Conclusions: This study proposes fostamatinib, pralatrexate and entecavir as possible candidates for drug repositioning. Additionally, the nine pharmacophores can be utilized in other drug databases for identifying new molecules and/or drugs with potential for drug repositioning. Further in silico and in vitro studies of the proposed drugs are recommended.
Downloads
References
Astudillo-de la Vega H, Ruiz-García E, Martínez-Cedillo J, Ochoa-Carrillo FJ. El papel de la quimiorresistencia en los tumores sólidos. Gac Mex Oncol [Internet]. 2010;9(3):117–26.
Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov [Internet]. 2021;20(10):741–69.
Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, et al. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell [Internet]. 2017;31(6):820-32
Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci [Internet]. 2020;11(23):5855–65.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov [Internet]. 2005;4(12):988–1004.
Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: Clinical implications and adverse effects. Int J Mol Sci [Internet]. 2021;22(7):3464.
Arafeh R, Samuels Y. PIK3CA in cancer: The past 30 years. Semin Cancer Biol [Internet]. 2019;59:36–49.
Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/ predictive biomarkers in early clinical trials. J Clin Oncol [Internet]. 2012;30(3):331–3.
Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, et al. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol [Internet]. 2017;50(2):606–12.
Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J [Internet]. 2007;404(1):15–21.
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov [Internet]. 2019;18(1):41–58.
Vulpetti A, Bosotti R. Sequence and structural analysis of kinase ATP pocket residues. Il Farm [Internet]. 2004;59(10):759–65.
Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebocontrolled trials. Am J Hematol [Internet]. 2018;93(7):921–30.
Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, et al. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol [Internet]. 2013;71(4):981–90.
Shinde A, Hardy SD, Kim D, Akhand SS, Jolly MK, Wang WH, et al. Spleen tyrosine kinase–mediated autophagy is required for epithelialmesenchymal plasticity and metastasis in breast cancer. Cancer Res [Internet]. 2019;79(8):1831–43. 16. Sung YM, Xu X, Sun J, Mueller D, Sentissi K, Johnson P, et al. Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLOS ONE [Internet]. 2009;4(10):e7445.
Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther [Internet]. 2006;319(3):998–1008.
Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer [Internet]. 2016;54:11–7.
Heffron TP, Heald RA, Ndubaku C, Wei B, Augistin M, Do S, et al. The rational design of selective benzoxazepin inhibitors of the α-isoform of phosphoinositide 3-Kinase culminating in the identification of ( S )-2-((2-(1-isopropyl-1 H -1,2,4-triazol-5-yl)-5,6-dihydrobenzo[ f ] imidazo[1,2- d ][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). J Med Chem [Internet]. 2016;59(3):985–1002.
Maheshwari S, Miller MS, O’Meally R, Cole RN, Amzel LM, Gabelli SB. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. J Biol Chem [Internet]. 2017;292(33):13541–50.
Clark RA, Lee S, Qiao J, Chung DH. Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells. Oncotarget [Internet]. 2020;11(32):3069–77.
Marchi E, O’Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol [Internet]. 2012;3(4):227–35.
Bae JY, Lee GE, Park H, Cho J, Kim J, Lee J, et al. Antiviral efficacy of pralatrexate against SARS-CoV-2. Biomol Ther (Seoul) [Internet]. 2021;29(3):268–72.
Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature [Internet]. 1999;402(6759):313–20.
Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, et al. Wortmannin inactivates phosphoinositide 3-Kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol [Internet]. 1996;16(4):1722–33.
Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66(12):1605–22.
Sherin DR, Manojkumar TK. Exploring the selectivity of guanine scaffold in anticancer drug development by computational repurposing approach. Sci Rep [Internet]. 2021;11(1):16251.
Lourenço T, Vale N. Pharmacological efficacy of repurposing drugs in the treatment of prostate cancer. Int J Mol Sci [Internet]. 2023;24(4):4154.
Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer [Internet]. 2018;13:19.
Brüning A, Burger P, Gingelmaier A, Mylonas I. The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. Invest New Drugs [Internet]. 2012;30(4):1389–95.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
